Lexicon Pharmaceuticals, Inc. (LXRX) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
LXRX Revenue Growth
Revenue Breakdown (FY 2025)
LXRX's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
LXRX Revenue Analysis (2014–2025)
As of May 8, 2026, Lexicon Pharmaceuticals, Inc. (LXRX) generated trailing twelve-month (TTM) revenue of $69.6 million, reflecting explosive growth of +1572.1% year-over-year. The most recent quarter (Q1 2026) recorded $21.1 million in revenue, up 284.2% sequentially.
Looking at the longer-term picture, LXRX's 5-year compound annual growth rate (CAGR) stands at +15.7%, indicating consistent double-digit revenue growth. The company achieved its highest annual revenue of $322.1 million in 2019.
Revenue diversification analysis shows LXRX's business is primarily driven by License (91%), and Product (9%). With over half of revenue concentrated in License, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including ARDX (+18.2% YoY), CORT (+12.2% YoY), and INVA (+13.6% YoY), LXRX has outperformed the peer group in terms of revenue growth. Compare LXRX vs ARDX →
LXRX Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| LXRXCurrent | $70M | +1572.1% | +15.7% | -98.2% | |
 ARDX | $407M | +18.2% | +121.9% | -10.1% | |
 CORT | $761M | +12.2% | +16.6% | 5.9% | |
 INVA | $425M | +13.6% | +4.8% | 38.5% | |
 PTGX | $46M | -91.5% | +10.0% | -343.6% | |
 ACAD | $1.1B | +9.9% | +19.4% | 9.8% |
LXRX Historical Revenue Data (2014–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $49.8M | +60.2% | $49.5M | 99.4% | $-48,911,000 | -98.2% |
| 2024 | $31.1M | +2481.5% | $30.5M | 98.0% | $-197,117,000 | -634.2% |
| 2023 | $1.2M | +766.2% | $-57,768,000 | -4798.0% | $-171,750,000 | -14265.0% |
| 2022 | $139K | -53.4% | $-52,377,000 | -37681.3% | $-100,760,000 | -72489.2% |
| 2021 | $298K | -98.8% | $-54,748,000 | -18371.8% | $-87,090,000 | -29224.8% |
| 2020 | $24.0M | -92.5% | $22.1M | 92.0% | $-47,800,000 | -199.2% |
| 2019 | $322.1M | +409.5% | $318.8M | 99.0% | $141.4M | 43.9% |
| 2018 | $63.2M | -30.0% | $60.7M | 96.1% | $-103,279,000 | -163.4% |
| 2017 | $90.3M | +8.4% | $88.4M | 97.9% | $-136,681,000 | -151.3% |
| 2016 | $83.3M | -35.9% | $-80,636,000 | -96.8% | $-137,155,000 | -164.6% |
See LXRX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs LXRX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare LXRX vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonLXRX — Frequently Asked Questions
Quick answers to the most common questions about buying LXRX stock.
Is LXRX's revenue growth accelerating or slowing?
LXRX revenue is accelerating at +1572.1% year-over-year, exceeding the 5-year CAGR of +15.7%. TTM revenue reached $70M. Growth momentum has increased versus prior periods.
What is LXRX's long-term revenue growth rate?
Lexicon Pharmaceuticals, Inc.'s 5-year revenue CAGR of +15.7% reflects the sustained expansion pattern. Current YoY growth of +1572.1% is above this long-term average.
How is LXRX's revenue distributed by segment?
LXRX reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.